Together, these findings clearly suggest that DSG2 is predictive of the progression‐free and overall survival of newly diagnosed MM patients, independent of NSD2 expression (and thus, by extension, the t(4;14) translocation), and potentially independent of routinely measured biomarkers of MM activity and/or prognosis. The gene discussed is DSG2; the disease is Miyoshi myopathy.